 |
Related Articles |
New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: a case-based approach for the primary care provider.
Curr Opin Pediatr. 2018 Dec 06;:
Authors: Partain PI, White J, Hammerness P
Abstract
PURPOSE OF REVIEW: To provide an up-to-date clinical review of U.S. Food and Drug Administration (FDA)-approved stimulant medications for attention-deficit/hyperactivity disorder (ADHD), including a framework for individualized treatment by primary care pediatric providers.
RECENT FINDINGS: Stimulant medications are first-line agents for pediatric ADHD. Since 2012, 11 novel stimulant medications have been approved by the FDA for the treatment of ADHD. Because of an expanded formulary of available methylphenidate-based and amphetamine-based stimulants, primary care providers may be unfamiliar with some novel medications outside a select formulary.
SUMMARY: The current broad formulary of methylphenidate-based and amphetamine-based stimulants provides primary care clinicians with a greater opportunity for personalized medicine within the patient-centered medical home. Through a systematic review of prior relevant medication trials, a consideration of daily symptom burden and thoughtful pragmatics, primary care providers can offer a more precise, customized stimulant treatment.
PMID: 30531224 [PubMed – as supplied by publisher]
via https://www.ncbi.nlm.nih.gov/pubmed/30531224?dopt=Abstract